Palisade Bio (NASDAQ:PALI) Research Coverage Started at HC Wainwright

HC Wainwright started coverage on shares of Palisade Bio (NASDAQ:PALI) in a research note issued to investors on Thursday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $7.00 price target on the stock.

Other research analysts also recently issued research reports about the company. Weiss Ratings restated a “sell (e+)” rating on shares of Palisade Bio in a research note on Thursday, January 22nd. Clear Str raised Palisade Bio to a “strong-buy” rating in a research note on Monday, December 29th. Stifel Nicolaus began coverage on Palisade Bio in a report on Wednesday, February 25th. They set a “buy” rating and a $5.00 price target for the company. Wall Street Zen raised Palisade Bio from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Piper Sandler started coverage on Palisade Bio in a report on Monday, December 29th. They issued an “overweight” rating and a $25.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Palisade Bio presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

Palisade Bio Stock Up 2.0%

Shares of NASDAQ:PALI opened at $2.00 on Thursday. The firm has a fifty day moving average of $1.78 and a two-hundred day moving average of $1.75. Palisade Bio has a 12-month low of $0.53 and a 12-month high of $2.64. The firm has a market capitalization of $331.76 million, a P/E ratio of -0.94 and a beta of 1.53.

Institutional Investors Weigh In On Palisade Bio

Several hedge funds have recently modified their holdings of the business. Creek Drive Management Group LLC acquired a new stake in shares of Palisade Bio in the fourth quarter worth $723,000. Caitong International Asset Management Co. Ltd acquired a new position in Palisade Bio during the 4th quarter valued at $81,000. Seven Fleet Capital Management LP acquired a new position in Palisade Bio during the 4th quarter valued at $770,000. Virtu Financial LLC bought a new stake in Palisade Bio in the 4th quarter valued at $28,000. Finally, XTX Topco Ltd boosted its holdings in Palisade Bio by 53.8% in the 4th quarter. XTX Topco Ltd now owns 21,669 shares of the company’s stock valued at $51,000 after purchasing an additional 7,584 shares during the period. 11.79% of the stock is owned by institutional investors.

Palisade Bio News Roundup

Here are the key news stories impacting Palisade Bio this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $7.00 price target — a sizable premium to the current price that could act as an upside catalyst if investors buy into the thesis. HC Wainwright initiates coverage
• Neutral Sentiment: HC Wainwright published detailed quarterly EPS projections showing modest per-quarter losses through 2027 (e.g., FY2026 EPS est. ($0.07); FY2027 EPS est. ($0.12)). These figures set near-term expectations for continued negative earnings but quantify the magnitude of losses. HC Wainwright estimates (MarketBeat)
• Neutral Sentiment: Market action shows increased interest: volume above its average and the stock trading above its 50- and 200-day moving averages. That technical setup can amplify reactions to news (both positive and negative). PALI market data (MarketBeat)
• Negative Sentiment: The reports also cite a consensus “current full-year” EPS of ($12.43), an unusually large figure that conflicts with HC Wainwright’s estimates and may reflect a data anomaly or signal materially different street expectations — either could create volatility or negative re-rating if clarified unfavorably. Consensus figure noted (MarketBeat)

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.